Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals

U.S. drugmaker Eli Lilly has entered into an agreement to collaborate ​on and possibly licence experimental ‌medicines from a unit of Haisco Pharmaceutical Group , with potential payments of up to around $3 ​billion if milestones are met, ​the Chinese drugmaker said Monday.